CVSIX
Price
$16.42
Change
+$0.02 (+0.12%)
Updated
Jul 15 closing price
Net Assets
18.23B
WMNIX
Price
$10.50
Change
-$0.00 (-0.00%)
Updated
Jul 15 closing price
Net Assets
174.53M
Interact to see
Advertisement

CVSIX vs WMNIX

CVSIX vs WMNIX Comparison Chart in %
View a ticker or compare two or three
VS
CVSIX vs. WMNIX commentary
Jul 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVSIX is a Hold and WMNIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CVSIX has more cash in the bank: 18.2B vs. WMNIX (175M). WMNIX pays higher dividends than CVSIX: WMNIX (1.85) vs CVSIX (1.42). CVSIX was incepted earlier than WMNIX: CVSIX (36 years) vs WMNIX (11 years). CVSIX (1.26) is less costly to investors than WMNIX (1.10). WMNIX is a more actively managed with annual turnover of: 89.00 vs. CVSIX (43.00). CVSIX has a lower initial minimum investment than WMNIX: CVSIX (2500) vs WMNIX (100000). WMNIX annual gain was more profitable for investors over the last year : 7.99 vs. CVSIX (6.32). WMNIX return over 5 years is better than : 25.45 vs. CVSIX (20.29).
CVSIXWMNIXCVSIX / WMNIX
Total Expense Ratio1.260.90140%
Annual Report Gross Expense Ratio1.261.10115%
Fund Existence36 years11 years-
Gain YTD3.2984.35376%
Front Load3%N/A-
Min. Initial Investment25001000003%
Min. Initial Investment IRAN/AN/A-
Net Assets18.2B175M10,400%
Annual Yield % from dividends1.421.8577%
Returns for 1 year6.327.9979%
Returns for 3 years17.3323.4274%
Returns for 5 years20.2925.4580%
Returns for 10 years39.8147.7683%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MVGKX18.040.02
+0.11%
MFS Low Volatility Global Equity R2
HSSCX27.19N/A
N/A
Emerald Bkg & Finac Evolution - C
FTEIX16.65N/A
N/A
Fidelity Advisor Total Intl Equity I
MRLVX35.15N/A
N/A
BlackRock Advantage Large Cap Val R
JEMWX52.70N/A
N/A
JPMorgan Emerging Markets Equity R6